SCHEMBL505412

SCHEMBL505412

O=C(O)c1ccccc1-c1ccc(-c2ccccc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HNF4A P41235 3/20 0.64
BCAT2 O15382 1/20 0.63
CDC25B P30305 1/20 0.59
ATM Q13315 1/20 0.59
FABP3 P05413 1/20 0.58
FABP4 P15090 1/20 0.58
FABP5 Q01469 1/20 0.58
SMN1; SMN2 Q16637 2/20 0.57
MEN1 O00255 1/20 0.57
KMT2A Q03164 1/20 0.57
ALDH1A1 P00352 2/20 0.56
ALOX15 P16050 1/20 0.56
PTPN1 P18031 1/20 0.55
CHRNB2 P17787 1/20 0.55
CHRNB4 P30926 1/20 0.55
CHRNA3 P32297 1/20 0.55
CHRNA4 P43681 1/20 0.55
NPC1 O15118 1/20 0.54
RAB9A P51151 1/20 0.54
LTB4R2 Q9NPC1 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32677772 1.00 HNF4A (0.64) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL32677769 1.00 HNF4A (0.64) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL11554621 0.98 HNF4A (0.61) HNF4ABCAT2CDC25BATMFABP3
Biphenyl SCHEMBL9292498 0.98 HNF4A (0.67) HNF4ABCAT2CDC25BATMFABP3
Benzene SCHEMBL28480917 0.95 HNF4A (0.69) HNF4ABCAT2CDC25BATMFABP3
Benzene SCHEMBL1403559 0.95 HNF4A (0.69) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL30292805 0.95 HNF4A (0.63) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL18759613 0.95 HNF4A (0.63) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL133057 0.95 HNF4A (0.69) HNF4ABCAT2CDC25BATMFABP3
SCHEMBL26624744 0.95 HNF4A (0.69) HNF4ABCAT2CDC25BATMFABP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738684-B2 N-terminally modified linear and branched polyamine conjugated peptidomimetics as antimicrobials agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-08-22 US claimed
US-20160376306-A1 N-Terminally Modified Linear and Branched Polyamine Conjugated Peptidomimetics as Antimicrobials Agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-29 US claimed
EP-0059983-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT THE WELLCOME FOUNDATION LIMITED (GB) 1986-06-11 EP claimed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 EP claimed
CN-110140245-B Nonaqueous electrolyte secondary battery and material used therein 三井化学株式会社 2022-10-25 CN disclosed
CN-110862368-B Photocatalytic oxidation synthesis method of benzocoumarin compound 浙江工业大学 2021-06-15 CN disclosed
CN-110862368-A Photocatalytic oxidation synthesis method of benzocoumarin compound 浙江工业大学 2020-03-06 CN disclosed
EP-2444120-B1 Spirocyclic amiloride analogues as ENac blockers NOVARTIS AG (CH) 2017-09-27 EP disclosed
US-9738684-B2 N-terminally modified linear and branched polyamine conjugated peptidomimetics as antimicrobials agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-08-22 US disclosed
US-9643983-B2 Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives NOVARTIS AG (CH) 2017-05-09 US disclosed
US-20160376306-A1 N-Terminally Modified Linear and Branched Polyamine Conjugated Peptidomimetics as Antimicrobials Agents COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2016-12-29 US disclosed
EP-2231280-B1 Amiloride-like Pyrazine-carboxamides as ENaC blockers NOVARTIS AG (CH) 2016-08-10 EP disclosed
WO-1999045925-A1 NOVEL OPIATE COMPOUNDS, METHODS OF MAKING AND METHODS OF USE RESEARCH TRIANGLE INSTITUTE (US) 1999-09-16 WO disclosed
EP-0891333-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 EP disclosed
WO-1997036875-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed
US-4777300-A Aromatic ketone IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-10-11 US disclosed
EP-0232992-A1 Aromatic ketone IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-08-19 EP disclosed
EP-0059983-B1 SUBSTITUTED BIPHENYL COMPOUNDS FOR USE AS A MEDICAMENT THE WELLCOME FOUNDATION LIMITED (GB) 1986-06-11 EP disclosed
US-4578522-A CHEMICAL INTERMEDIATES FOR BLOOD LIPID CONTROLLING COMPOUNDS BURROUGHS WELLCOME CO. 1986-03-25 US disclosed
EP-0059983-A1 Substituted biphenyl compounds for use as a medicament THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376306-A1 N-Terminally Modified Linear and Branched Polyamine Conjugated Peptidomimetics as Antimicrobials Agents SRM, CD14, SMS HNF4A 4634/4885BCAT2 936/4885CDC25B 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.